The Briefing
News and stories from the people building it: Deep Tech, Biopharma Deals, AI, Energy, Planet & Space
Tribute · Leadership
Make it so: Sir Patrick Stewart and the calm way to lead
As Captain Picard he showed a generation how a calm leader asks first and decides once everyone has spoken.
New service · Advisory
The Focus Block: from the big goal to the next move
Ten sessions over 90 days for leaders whose goal takes months, built on one method for change.
Conversation · Deep tech
Sell it before you build it
Philipp Baaske co-founded NanoTemper and grew it on customers’ money, selling his first device before it existed.
Article · Biopharma deals
$358 million for the right to wait
Boehringer Ingelheim pays about $60 million a programme for six Sino Biopharm cancer programmes that no patient has received yet.
Conversation · Biotech
Beyond one drug
Christoph Lengauer was founding CSO of Blueprint Medicines and co-founded Thrive Earlier Detection; today he is co-founder and CSO of Curie.Bio. Why a biotech needs a product engine instead of a single bet, and why investors back the A team over the A idea.
New handbook · Advisory
How to make a big decision
My three-step method, Your Next Move, is now a free handbook: prepare the decision in writing, work it through in sixty minutes and leave with one step and a date.
From the article
Conversations Long-form, with questions answered and the full transcript
Beyond one drug
Sell it before you build it
Can AI fix drug discovery?
Great science, missed patients
Today’s top deals Five a day across biopharma, AI and deep tech, with why each one matters
5 November 2026Subscribe to the newsletterAll five with the details →
Pharma M&A · US / Sweden · 5 Nov
ANI Pharmaceuticals offers about $560M for Egetis Therapeutics
Why it matters: A US specialty pharma company buys a newly approved European rare-disease drug, and the voucher sale pays for about a third of the price.
Source: GlobeNewswire ↗
Biotech financing · UK · 5 Nov
T-Therapeutics raises a $133M Series B to take two TCR bispecifics into the clinic
Why it matters: One of the larger UK Series B rounds, with the venture arms of Lilly, J&J and Sanofi all on the cap table.
Source: GlobeNewswire ↗
AI chips & optics M&A · US · 2 Nov
Marvell agrees to buy Lumentum in an all-stock deal worth about $115B
Why it matters: Optical links between chips are now a bottleneck for AI data centres. Light Reading reports it as the largest public tech acquisition on record.
Source: Light Reading ↗
Biotech financing · UK · 5 Nov
Oxford spinout Alethio Therapeutics raises a $90M Series A
Why it matters: A US crossover investor co-leads a large preclinical round in the UK. Together with T-Therapeutics, two UK biotech companies raised $223M in one day.
Source: BioPharma Dive ↗
AI security financing · US / Israel · 4 Nov
Sentra raises a $150M Series C to secure the data AI agents can reach
Why it matters: Securing AI agents is turning into a category of its own, and large financial investors now back it.
Source: SecurityWeek ↗
Articles & deep dives Analysis, read the way a board would
Your company’s story in this format
Leadership teams who want their story told in this format work with me through my PR process.
See the PR process